Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Shelley McClure

Endocrinology, Diabetes & Metabolism Norman, OK Nurse Practitioner

NPI 1184392649 CMS profile 10638662

2260 36Th Ave Nw Ste 110, Norman, OK 73072

Open in the dashboard

General payments

$2,620

107 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shelley McClure of Norman, OK is reported in the CMS Open Payments database as having received $2,620 across 107 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $886 41
2024 General $305 5
2023 General $66 3
2022 General $836 39
2021 General $527 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shelley McClure
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Shelley McClure were reported at $886. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Shelley McClure Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $0 $494 $123–$2,253 $163
2020 $0 $335 $85–$1,841 $114
2021 $527 $398 $88–$1,981 $132
2022 $836 $364 $88–$1,568 $149
2023 $66 $420 $113–$1,614 $160
2024 $305 $440 $121–$1,646 $164
2025 $886 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Corcept Therapeutics $483 15 payments
  2. Sanofi-Aventis U.S. LLC $335 14 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $285 9 payments
  4. Dexcom, Inc. $244 10 payments
  5. Xeris Pharmaceuticals, Inc. $198 13 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $192 11 payments
  7. Lilly USA, LLC $163 9 payments
  8. AstraZeneca Pharmaceuticals LP $125 1 payment
  9. Daiichi Sankyo Inc. $122 1 payment
  10. Mannkind Corporation $70 2 payments
  11. Other $404 22 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,578 106 payments
  2. Education $43 1 payment
Products named General payments · program years 2021–2025
  1. Korlym $483 15 payments
  2. SOLIQUA 100/33 $301 12 payments
  3. Kerendia $285 9 payments
  4. JARDIANCE $192 11 payments
  5. Dexcom G6 Transmitter $188 7 payments
  6. RECORLEV $186 12 payments
  7. FARXIGA $125 1 payment
  8. INJECTAFER $122 1 payment
  9. SYNJARDY $80 4 payments
  10. AFREZZA $70 2 payments
  11. Other $841 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

107 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record